Form 4: Gilead CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Gilead Sciences CEO Daniel O'Day sold 10,000 shares of common stock on October 28, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel Patrick O'Day, Chairman & CEO and Director of Gilead Sciences, Inc. (GILD), reported the sale of common stock.
• The transactions occurred on October 28, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
• A total of 7,978 shares were sold at an average price of $119.5371 per share, with individual sale prices ranging from $119.08 to $120.06.
• An additional 2,022 shares were sold at an average price of $118.8223 per share, with individual sale prices ranging from $118.61 to $119.06.
• Following these transactions, Daniel O'Day beneficially owns 581,203 shares of Gilead Sciences common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sale was conducted under a pre-arranged 10b5-1 plan, which is a common personal financial planning tool for executives and does not necessarily reflect a change in company fundamentals or management's confidence.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on immediate, non-public information, which enhances transparency.

Negatives

• The sale by a high-ranking executive, even if planned, reduces their direct equity stake in the company, which some investors might interpret as a slight reduction in alignment of interests.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports a routine insider stock transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale represents a reduction in the CEO's direct equity ownership, which is a routine disclosure for insider transactions.

Key Dates

Recommendation

The reported insider sale by the CEO, executed under a pre-arranged 10b5-1 plan, is a personal financial event and does not provide new information that would fundamentally alter the investment thesis for Gilead Sciences. Such planned sales are common and typically do not signal a change in the company's operational outlook or management's long-term confidence. Therefore, a 'hold' recommendation is maintained, pending further operational or financial disclosures.

Keywords

Gilead Sciences, GILD, Daniel O'Day, Insider Transaction, Form 4, Stock Sale, 10b5-1 Plan, CEO